GIST

Latest News


Latest Videos


CME Content


More News

The phase III VOYAGER study may soon introduce a new treatment option for patients with locally advanced metastatic or unresectable gastrointestinal stromal tumors, a patient population with an unmet need for novel agents that are durable and can target specific drivers. The trial is looking at the efficacy of novel drug avapritinib versus standard-of-care regorafenib.<br /> &nbsp;

In the phase III INVICTUS trial, ripretinib, a novel KIT and PDGFRA inhibitor, demonstrated a dramatic improvement in progression-free survival compared with placebo in heavily pretreated patients with heavily advanced gastrointestinal stromal tumors, according to data presented at the 2019 ESMO Congress.

An objective response rate of 35.5% was seen with&nbsp;treatment with pemigatinib, a selective oral inhibitor of&nbsp;FGFR1, 2, and 3, in patients with&nbsp;previously treated, locally advanced or metastatic cholangiocarcinoma with an&nbsp;<em>FGFR2&nbsp;</em>rearrangement or fusion,&nbsp;according to findings from the phase II FIGHT-202 clinical trial presented at ESMO 2019.

Ripretinib demonstrated a significantly improved progression-free survival compared with placebo in patients with gastrointestinal stromal tumors being treated in the fourth-line setting or beyond, according to topline results from the phase III INVICTUS trial. An NDA for ripretinib is planned for the first quarter of 2020.&nbsp;

Laura Dawson, MD, FRCPC, FASTRO, has been selected as the president-elect of the American Society for Radiation Oncology and will begin her term at the society&rsquo;s 61st Annual Meeting, which is being held in Chicago, Illinois on September 15-18.

A prefilled syringe of&nbsp;lanreotide has been approved by the FDA to&nbsp;enable healthcare providers to administer the injection easier to adults with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.

ABP 980, a trastuzumab biosimilar, has been approved by the FDA&nbsp; for the treatment of patients with HER2-overexpressing breast cancer as well as HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, marking the fifth approval by the agency for a trastuzumab biosimilar.

During a recent&nbsp;<em>Targeted Oncology&nbsp;</em>live case-based peer perspectives presentation, Tanios Bekaii-Saab, MD, discussed with a group of physicians the treatment options for patients with gastrointestinal cancers and the characteristics that influence his decision making. Bekaii-Saab explained his clinical decisions based on the case scenario of one patient with colorectal cancer and one with hepatocellular carcinoma.